Advanced

TLR-3 polymorphism is an independent prognostic marker for stage II colorectal cancer

Castro, F. A.; Försti, Asta LU ; Buch, S.; Kalthoff, H.; Krauss, C.; Bauer, M.; Egberts, J.; Schniewind, B.; Broering, D. C. and Schreiber, S., et al. (2011) In European Journal of Cancer 47(8). p.1203-1210
Abstract
Background: Clinicopathologic stage is still the main parameter to evaluate the prognosis of newly diagnosed colorectal cancer (CRC) patients. Although molecular markers have been suggested for follow up of treated CRC patients, their complete clinical application is still under evaluation. Materials and methods: To evaluate the association of immune-related genes with CRC prognosis and survival, a total of 19 single nucleotide polymorphisms (SNPs) were genotyped in 614 German patients within the Kiel cohort (POPGEN). Results: A promoter variant (rs1800872) in the Interleukin-10 (IL-10) gene was associated with an increased lymph node metastasis involvement [odds ratio (OR) = 2.1, 95% confidence interval (CI) = 1.03-4.2, for carriers of... (More)
Background: Clinicopathologic stage is still the main parameter to evaluate the prognosis of newly diagnosed colorectal cancer (CRC) patients. Although molecular markers have been suggested for follow up of treated CRC patients, their complete clinical application is still under evaluation. Materials and methods: To evaluate the association of immune-related genes with CRC prognosis and survival, a total of 19 single nucleotide polymorphisms (SNPs) were genotyped in 614 German patients within the Kiel cohort (POPGEN). Results: A promoter variant (rs1800872) in the Interleukin-10 (IL-10) gene was associated with an increased lymph node metastasis involvement [odds ratio (OR) = 2.1, 95% confidence interval (CI) = 1.03-4.2, for carriers of the TT genotype]. More importantly, among 582 followed up patients the SNP rs3775291 in the toll-like receptor 3 (TLR-3) gene was associated with CRC specific survival (150 events). Patients carrying the TT genotype had a 93% increased risk of death compared with the CC carriers [hazard ratio (HR) = 1.93, 95% CI 1.14-3.281. The observed effect of the TLR-3 variant was restricted to stage II patients (HR = 4.14, 95% CI 1.24-13.84) and to patients who did not receive adjuvant therapy (HR = 3.2, 95% CI 1.4-7.7). Conclusions: Our results may provide additional candidates for risk assessment in stage II CRC patients for treatment decision. Further validation of the presented findings is warranted. (C) 2010 Elsevier Ltd. All rights reserved. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Alimentary tract, Variants, Prognosis and survival
in
European Journal of Cancer
volume
47
issue
8
pages
1203 - 1210
publisher
IFAC & Elsevier Ltd.
external identifiers
  • wos:000291232400010
  • scopus:79955531832
ISSN
1879-0852
DOI
10.1016/j.ejca.2010.12.011
language
English
LU publication?
yes
id
ab5e281d-4484-4420-af59-2342739d20a9 (old id 1985492)
date added to LUP
2011-07-01 09:04:56
date last changed
2017-06-25 03:00:45
@article{ab5e281d-4484-4420-af59-2342739d20a9,
  abstract     = {Background: Clinicopathologic stage is still the main parameter to evaluate the prognosis of newly diagnosed colorectal cancer (CRC) patients. Although molecular markers have been suggested for follow up of treated CRC patients, their complete clinical application is still under evaluation. Materials and methods: To evaluate the association of immune-related genes with CRC prognosis and survival, a total of 19 single nucleotide polymorphisms (SNPs) were genotyped in 614 German patients within the Kiel cohort (POPGEN). Results: A promoter variant (rs1800872) in the Interleukin-10 (IL-10) gene was associated with an increased lymph node metastasis involvement [odds ratio (OR) = 2.1, 95% confidence interval (CI) = 1.03-4.2, for carriers of the TT genotype]. More importantly, among 582 followed up patients the SNP rs3775291 in the toll-like receptor 3 (TLR-3) gene was associated with CRC specific survival (150 events). Patients carrying the TT genotype had a 93% increased risk of death compared with the CC carriers [hazard ratio (HR) = 1.93, 95% CI 1.14-3.281. The observed effect of the TLR-3 variant was restricted to stage II patients (HR = 4.14, 95% CI 1.24-13.84) and to patients who did not receive adjuvant therapy (HR = 3.2, 95% CI 1.4-7.7). Conclusions: Our results may provide additional candidates for risk assessment in stage II CRC patients for treatment decision. Further validation of the presented findings is warranted. (C) 2010 Elsevier Ltd. All rights reserved.},
  author       = {Castro, F. A. and Försti, Asta and Buch, S. and Kalthoff, H. and Krauss, C. and Bauer, M. and Egberts, J. and Schniewind, B. and Broering, D. C. and Schreiber, S. and Schmitt, M. and Hampe, J. and Hemminki, Kari and Schafmayer, C.},
  issn         = {1879-0852},
  keyword      = {Alimentary tract,Variants,Prognosis and survival},
  language     = {eng},
  number       = {8},
  pages        = {1203--1210},
  publisher    = {IFAC & Elsevier Ltd.},
  series       = {European Journal of Cancer},
  title        = {TLR-3 polymorphism is an independent prognostic marker for stage II colorectal cancer},
  url          = {http://dx.doi.org/10.1016/j.ejca.2010.12.011},
  volume       = {47},
  year         = {2011},
}